Tech-savvy Indonesians go off-grid to help to remote villages fight virus

1 / 4
Relawan Merahb Putih handed over their assistance to officials in the Duma village of North Maluku regency during a campaign to spread awareness of the pandemic. (Photo credit: Relawan Merah Putih/Komunitas Manyawa)
2 / 4
Microbiologist and volunteer adviser Jubhar Mangimbulude explains about the coronavirus to villagers during the awareness campaign. (Photo credit: Relawan Merah Putih/Komunitas Manyawa)
3 / 4
Microbiologist and volunteer adviser Jubhar Mangimbulude explains about the coronavirus to villagers during the awareness campaign. (Photo credit: Relawan Merah Putih/Komunitas Manyawa)
4 / 4
Microbiologist and volunteer adviser Jubhar Mangimbulude explains about the coronavirus to villagers during the awareness campaign. (Photo credit: Relawan Merah Putih/Komunitas Manyawa)
Short Url
Updated 04 July 2020

Tech-savvy Indonesians go off-grid to help to remote villages fight virus

  • Young volunteers tackle tough terrain, pandemic myths in isolated northern region

JAKARTA: A group of tech-savvy young locals in Indonesia’s northern North Halmahera regency is spreading awareness about the dangers of COVID-19 in remote corners of the archipelago at a time when bureaucracy has impeded a rapid response to the pandemic.

The Relawan Merah Putih, or Red and White Volunteers, includes a multimedia expert, university students, lecturers, civil servants and a web developer in Tobelo, the main city of North Halmahera in North Maluku province, about 2,500 km from the capital Jakarta.

The city is located on Halmahera island, part of the Maluku Islands, Indonesia’s fabled Spice Islands on the northeastern part of the sprawling archipelago.

Stevie Recaldo Karimang, a 28-year-old freelance photographer and videographer, told Arab News that he set up the group after social restrictions introduced to counter the pandemic put him out of business. 

He quickly developed a website on the pandemic and created online flyers and audiovisual materials that he and 31 other volunteers distributed on social media platforms and messaging apps to educate the public about the pandemic soon after the first cases in Indonesia were confirmed in Jakarta in early March.

“We translated the information we took from the national COVID-19 task force into the market language spoken here, which is a mixture of Indonesian and the local dialect, to make it more understandable for the locals,” Karimang said.

The group also used a drone to issue public warnings against mass gatherings.

“The drone helped to remind people not to form a crowd when social restrictions were enforced. We attached a flashlight to the device to catch the crowd’s attention, and we were able to dismiss such gatherings.”

But the volunteers shifted their efforts to rural areas after the first coronavirus case in North Maluku province was confirmed on March 23.

Jubhar Mangimbulude, a microbiology expert at Halmahera University and the group’s adviser, said the team had visited 30 isolated villages out of 196 townships in the regency, which is home to 161 million people.

“We reached one village after hours of driving over rough terrain. We have to use four-wheel-drive vehicles because along the way we may have to cross a river where the bridge is damaged,” he told Arab News.

Mangimbulude said that many villagers were unaware of the pandemic and only knew from TV that a dangerous virus was spreading quickly and infecting people. He was glad to find that no COVID-19 cases had been detected among the villagers.

But he acknowledged that misinformation was rife and said that he had to debunk myths about “how alcohol could be used to prevent the disease.”

“The villagers heard that the virus can be killed with heat in one’s body, and since drinking alcohol can warm the body, they encouraged their children and elders to drink a local alcoholic beverage made of fermented sugar palm fruit,” Mangimbulude said.

Fellow volunteer Oscar Berthomene, a local civil servant, said that the group was able to move faster than the regency administration whose bureaucracy slowed down the response to the pandemic.

“I have support from my supervisor, and we were able to help their activities with cars to allow them to move around,” he told Arab News.

The regency has about 18 percent of the 953 cases in the province, which make up about 1.5 percent of the national total of 62,142 as of Saturday.


US to pay over $1 bn for 100 mln doses of J&J’s potential COVID-19 vaccine

Updated 05 August 2020

US to pay over $1 bn for 100 mln doses of J&J’s potential COVID-19 vaccine

  • The latest contract equates to roughly $10 per vaccine dose produced by J&J
  • This is J&J’s first deal to supply its investigational vaccine to a country

WASHINGTON: The United States government will pay Johnson & Johnson over $1 billion for 100 million doses of its potential coronavirus vaccine, its latest such arrangement as the race to tame the pandemic intensifies, the drugmaker said on Wednesday.
It said it would deliver the vaccine to the Biomedical Advanced Research and Development Authority (BARDA) on a not-for-profit basis to be used after approval or emergency use authorization by the US Food and Drug Administration (FDA).
J&J has already received $1 billion in funding from the US government — BARDA agreed in March to provide that money for the company to build manufacturing capacity for more than 1 billion doses of the experimental vaccine.
The latest contract equates to roughly $10 per vaccine dose produced by J&J. Including the first $1 billion deal with the USgovernment, the price would be slightly higher than the $19.50 per dose that the United States is paying for the vaccine being developed by Pfizer Inc. and German biotech BioNTech SE.
The US government may also purchase an additional 200 million doses under a subsequent agreement. J&J did not disclose that deal’s value.
J&J plans to study a one- or two-dose regimen of the vaccine in parallel later this year. A single-shot regimen could allow more people to be vaccinated with the same number of doses and would sidestep issues around getting people to come back for their second dose.
This is J&J’s first deal to supply its investigational vaccine to a country. Talks are underway with the European Union, but no deal has yet been reached.
J&J’s investigational vaccine is currently being tested on healthy volunteers in the United States and Belgium in an early-stage study.
There are currently no approved vaccines for COVID-19. More than 20 are in clinical trials.